Sanofi: encouraging results in type 1 diabetes
(CercleFinance.com) - On Wednesday, Sanofi unveiled Phase III data showing that its monoclonal antibody Tzield has the potential to slow the onset of type 1 diabetes in children and adolescents.
The trial met its primary endpoint of improved beta-cell preservation, as evidenced by a significant slowing of the decline in mean C-peptide levels compared with placebo.
This "significant" difference shows that Tzield has the potential to slow progression to clinical (or stage 3) type 1 diabetes in children and adolescents, Sanofi says.
However, the main secondary endpoints, which included glycated hemoglobin (HbA1c), hypoglycemia episodes and insulin administration, did not reach statistical significance, says Sanofi.
This new data is being presented today at the International Society of Pediatric and Adolescent Diabetes (ISPAD) congress in Rotterdam (Netherlands).
Type 1 diabetes is a chronic autoimmune disease caused by the destruction of insulin-secreting beta cells.
Sanofi shares were flat on Wednesday following these announcements.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The trial met its primary endpoint of improved beta-cell preservation, as evidenced by a significant slowing of the decline in mean C-peptide levels compared with placebo.
This "significant" difference shows that Tzield has the potential to slow progression to clinical (or stage 3) type 1 diabetes in children and adolescents, Sanofi says.
However, the main secondary endpoints, which included glycated hemoglobin (HbA1c), hypoglycemia episodes and insulin administration, did not reach statistical significance, says Sanofi.
This new data is being presented today at the International Society of Pediatric and Adolescent Diabetes (ISPAD) congress in Rotterdam (Netherlands).
Type 1 diabetes is a chronic autoimmune disease caused by the destruction of insulin-secreting beta cells.
Sanofi shares were flat on Wednesday following these announcements.
Copyright (c) 2023 CercleFinance.com. All rights reserved.